KPTI实时信号 | 通过Getagraph.com最大化利润

购买 105151 min ago

@ $1.418

发出时间: 15 Feb 2024 @ 04:43

回报率: -25.25%

上一信号: Feb 14 - 01:41

上一信号: 出售

回报率: 12.54 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	652 441
平均成交量	1.79M
市值	123.45M
EPS	$0 ( 2024-02-29 )
下一个收益日期	( $-0.330 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.850
ATR14	$0.00200 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Rangwala Reshma	Sell	6 789	Common Stock
2024-04-04	Paulson Richard A.	Sell	3 563	Common Stock
2024-03-05	Paulson Richard A.	Sell	3 573	Common Stock
2024-02-29	Rangwala Reshma	Sell	15 667	Common
2024-03-01	Rangwala Reshma	Sell	5 969	Common

INSIDER POWER
69.84
Last 99 transactions
Buy: 2 857 011 \| Sell: 554 783

音量相关性

長: -0.29 (neutral)

短: -0.93 (very strong negative)

Signal:(25.667) Possible Trading Opportunity Present (swing)

Karyopharm Therapeutics 相关性

10 最正相关
RMRM	0.914
GAINL	0.87

10 最负相关
BRAG	-0.833
EM	-0.806
AVTE	-0.804
ARCE	-0.803

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Karyopharm Therapeutics 相关性 - 货币/商品

0.00
( neutral )

0.50
( neutral )

Karyopharm Therapeutics 财务报表

Annual	2023
营收:	$146.03M
毛利润:	$140.56M (96.25 %)
EPS:	$-1.250

FY	2023
营收:	$146.03M
毛利润:	$140.56M (96.25 %)
EPS:	$-1.250

FY	2022
营收:	$157.07M
毛利润:	$151.86M (96.68 %)
EPS:	$-2.02

FY	2021
营收:	$209.82M
毛利润:	$206.42M (98.38 %)
EPS:	$-1.650

Financial Reports:

No articles found.

Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

实时更新： Karyopharm Therapeutics [KPTI]

Upcoming Earnings Alert